Lördag 7 Juni | 13:58:53 Europe / Stockholm

Prenumeration

2025-05-23 10:04:00

Preliminary results from the first patient cohort in Elicera Therapeutics’ ongoing phase I/IIa CARMA study with the drug candidate ELC-301 was presented at the 7th Swedish Cancer Research Meeting in Malmö yesterday. The results show that two out of three treated patients had no active lymphoma disease, thus achieving complete metabolic response. We contacted CEO Jamal El-Mosleh for a comment.

Read the full interview at biostock.se:

https://biostock.se/en/2025/05/promising-preliminary-results-for-elicera-therapeutics-car-t-cell-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/